This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dekkers, O. M. Articles by Vandenbroucke, J. P. Search for Related Content PubMed PubMed Citation Articles by Dekkers, O. M. Articles by Vandenbroucke, J. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Mortality in Acromegaly: A Metaanalysis

Departments of Endocrinology and Metabolic Diseases (O.M.D., N.R.B., A.M.P., J.A.R.) and Clinical Epidemiology (O.M.D., J.P.V.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Address all correspondence and requests for reprints to: O. M. Dekkers, M.D., M.A., Department of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: o.m.dekkers{at}lumc.nl.

Context: Several studies have assessed mortality risk in patients treated for acromegaly. All studies found a mortality that was higher than expected for the general population, but most of these increases were not statistically significant. For this reason, it is not formally established whether mortality in acromegaly is different from the general population.

Objective: The objective of the study was to address the all-cause mortality risk in patients with acromegaly.

Design: The study was a metaanalysis.

Methods: Sixteen studies on mortality in patients with acromegaly were included. The principal outcome of the metaanalysis was the weighted average of the standardized mortality ratio (SMR) of all studies. In addition, we performed a subgroup analysis of studies in which more than 80% of the patients were treated by transsphenoidal approach.

Results: The weighted mean of the SMR from all 16 studies was 1.72 (95% confidence interval 1.62–1.83). In studies with transsphenoidal surgery as the primary therapy, the weighted mean of the SMR was 1.32 (95% confidence interval 1.12–1.56).

Conclusions: This metaanalysis shows increased all-cause mortality in acromegalic patients, compared with the general population, even after transsphenoidal surgery.

This article has been cited by other articles:

				M. Sherlock, R. C. Reulen, A. A. Alonso, J. Ayuk, R. N. Clayton, M. C. Sheppard, M. M. Hawkins, A. S. Bates, and P. M. Stewart ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4216 - 4223. [Abstract] [Full Text] [PDF]

				A. Colao, R. S. Auriemma, M. Galdiero, G. Lombardi, and R. Pivonello Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3746 - 3756. [Abstract] [Full Text] [PDF]

				C L Ronchi, C Giavoli, E Ferrante, E Verrua, S Bergamaschi, D I Ferrari, S Corbetta, L Montefusco, M Arosio, B Ambrosi, et al. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments Eur. J. Endocrinol., July 1, 2009; 161(1): 37 - 42. [Abstract] [Full Text] [PDF]

				S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, et al. Guidelines for Acromegaly Management: An Update J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1509 - 1517. [Abstract] [Full Text] [PDF]

				N. Friedrich, R. Haring, M. Nauck, J. Ludemann, D. Rosskopf, E. Spilcke-Liss, S. B. Felix, M. Dorr, G. Brabant, H. Volzke, et al. Mortality and Serum Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein 3 Concentrations J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1732 - 1739. [Abstract] [Full Text] [PDF]

				N. Moller and J. O. L. Jorgensen Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects Endocr. Rev., April 1, 2009; 30(2): 152 - 177. [Abstract] [Full Text] [PDF]

				M. Sherlock, E. Fernandez-Rodriguez, A. A. Alonso, R. C. Reulen, J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, A. Bates, and P. M. Stewart Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1255 - 1263. [Abstract] [Full Text] [PDF]

				A. Beckers Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2975 - 2977. [Full Text] [PDF]

				I M Holdaway, M J Bolland, and G D Gamble A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly Eur. J. Endocrinol., August 1, 2008; 159(2): 89 - 95. [Abstract] [Full Text] [PDF]